Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
XOM Exxon Mobil Corp
CMI Cummins Inc
OILX UBS ETRACS S&P GSCI Crude Oil Total Return Index ETN
RUN Sunrun Inc
BAC Bank of America Corp
HLT Hilton Worldwide Holdings Inc
MNMT Motivating Masses Inc
FTA.IV First Trust Large Cap Value Oppts Alpha
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Mid Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Closing Price
$132.05
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
1,927,305
0

UPDATE: AMD stock slides after earnings as revenue forecast comes in light

6:25 pm ET July 30, 2019 (MarketWatch)
Print

By Wallace Witkowski, MarketWatch

AMD sees third-quarter sales of up to $1.85 billion, Street expected $1.94 billion

Advanced Micro Devices Inc. shares dropped in the extended session Tuesday after the chip maker reported earnings that met expectations amid tariff constraints, but disclosed a revenue outlook that fell below the Wall Street consensus because of weaker-than-expected console sales.

AMD (AMD) shares, which had fallen more than 5% after hours, were last down 3%, following a 1.2% rise in the regular session to close at $33.87. In comparison, the S&P 500 index declined 0.3%, the tech-heavy Nasdaq Composite Index slipped 0.2%, and the PHLX Semiconductor Index declined 0.3% in the regular session.

AMD expects third-quarter revenue of $1.75 billion to $1.85 billion, while analysts had forecast sales of $1.94 billion on average, according to FactSet.

Read: Microsoft is killing it in all businesses except for one (http://www.marketwatch.com/story/microsoft-is-killing-it-in-all-businesses-except-for-one-2019-07-18)

"The sequential and year-over-year increases are expected to be driven by rising EPYC, and Radeon product sales, partially offset by lower than expected semicustom sales," said Devinder Kumar, AMD chief financial offer, on the call. Chips for game consoles fall into AMD's semicustom sales.

"AMD met expectations for the quarter, but took its forecast down based on softness in the game console market," Pat Moorhead, principal analyst at Moor Insights and Strategy, said in emailed comments.

"I believe this softness is driven by consumers getting excited for the next-generation consoles from Microsoft (MSFT) (Scarlett) and Sony (PS5) and delaying purchases," Moorhead said. "Supporting this, Microsoft and Sony console sales recently were also both down."

For more: Microsoft is killing it in all businesses except for one (http://www.marketwatch.com/story/microsoft-is-killing-it-in-all-businesses-except-for-one-2019-07-18)

"In the second quarter, we stopped shipping to customers added to the U.S. entities list," AMD Chief Executive Lisa Su said on the conference call. "While we remain cautious, given the fluidity of the situation, the impact to date has been limited and offset by growing momentum in other parts of our business."

The company reported second-quarter net income of $35 million, or 3 cents a share, compared with $116 million, or 11 cents a share, in the year-ago period. Adjusted earnings were 8 cents a share. Revenue declined to $1.53 billion from $1.76 billion in the year-ago quarter.

Analysts surveyed by FactSet had forecast earnings of 8 cents a share on revenue of $1.52 billion.

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 30, 2019 18:25 ET (22:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.